Stock Region Penny Picks
Welcome to the Sunday Night Stock Region Wrap-Up! ☕️📈
Welcome to the Sunday Night Stock Region Wrap-Up! ☕️📈
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
DISCLAIMER: The following newsletter is for informational and entertainment purposes only. I am not a certified financial advisor, and nothing in this email constitutes financial, investment, or legal advice. Trading stocks, especially volatile small-caps and biotechs, involves significant risk. Always do your own due diligence (DD) and consult with a professional before putting your hard-earned money on the line.
Happy Sunday, Stock Region family! Grab a coffee, or maybe something stronger if your portfolio had a rough week. We’ve got a lot to unpack from the last few days (May 6th - 8th). The market has been throwing everything at us—massive earnings beats, biotech drama, and enough AI and blockchain buzzwords to make your head spin.
Let’s cut through the noise, separate the actual catalysts from the fluff, and build out our watchlists for the week ahead.
Here’s my take on what went down.
🔥 The Earnings Crushers: Respect the Fundamentals
Let’s start with the stuff that actually matters: cold, hard cash. A few companies completely knocked it out of the park this week, and honestly, it’s refreshing to see.
$SENS (Senseonics): Wow. Just wow. They reported a Q1 revenue of $11.7M—an 87% year-over-year increase. They raised their full-year guidance to $60M-$64M and are pushing hard with the Eversense® 365 launch in Europe. They also secured over $100M in financing to back their commercial strategy. My take: This is how you execute a growth strategy. The cash runway gives them breathing room, and the YoY growth is undeniably strong. Keep this on high alert.
$CRSR (Corsair): The gamers are still spending! Corsair posted a record Q1 gross margin of 32.7% and a massive 58% YoY increase in Adjusted EBITDA to $35.8M. My take: Hardware can be a brutal sector, but Corsair is showing serious operational efficiency here. Profit growth like this doesn’t happen by accident.
$SABR (Sabre): Who had Sabre staging a comeback on their 2026 bingo card? They reported $0.06 per share, absolutely destroying the analyst estimate of $(0.03) by 300%. My take: Travel tech has been a wild ride, but beating estimates this heavily shows they are navigating the post-recovery environment better than Wall Street thought.
$BLMN (Bloomin’ Brands): The folks behind Outback Steakhouse served up a juicy quarter. Earnings beat by 17.5% ($0.67 vs $0.57 est). My take: Never underestimate the American consumer’s desire for a Bloomin’ Onion. Solid, defensive play.
🧬 Biotech Roulette: The High-Risk, High-Reward Corner
You know I have a love/hate relationship with biotechs. The highs are euphoric, and the lows will make you sick to your stomach.
$IFRX (InflaRx): A classic biotech double-edged sword. On one hand, they announced the advancement of Izicopan for renal diseases (yay!). On the exact same day, they announced a $150 million share offering (boo!). My take: It’s incredibly frustrating for retail traders when a company dilutes immediately on good news. The cash will help their pipeline, but expect the share price to feel the weight of that $150M paper drop for a bit.
$ATRA (Atara Biotherapeutics): They just had a Type A meeting with the FDA regarding a Complete Response Letter (CRL) for Tabelecleucel. My take: FDA drama is stressful. Keep an eye on the actual minutes from that meeting. If the FDA’s concerns are easily addressable, this could bounce. If not, look out below.
$PSTV (Plus Therapeutics) & $TRAW (Traws Pharma): PSTV is showing favorable safety and survival data for leptomeningeal metastases (a devastating cancer complication), and TRAW is advancing candidates for Hantavirus. My take: Both are tackling incredibly tough diseases. PSTV’s data sounds genuinely promising for a high-unmet-need area.
🤖 Tech & Buzzword Bingo: Show Me the Money
Everyone wants to be a tech company right now. Let’s look at who is actually building and who is just writing good press releases.
$RXT (Rackspace) & AMD: They signed an MOU to build a “New Category of Governed Enterprise AI Infrastructure.” My take: When a behemoth like AMD is involved, you pay attention. This isn’t just fluff; enterprise AI needs secure, governed infrastructure. This is a real partnership to watch.
$GLE (Global Engine Group): They signed an MOU to explore integrating “Satellite Networks, Data Infrastructure, and Blockchain Technology to Support AI.” My take: I’m going to be brutally honest—this sounds like they just Googled “top trending tech words 2026” and jammed them into a headline. I need to see actual execution before I buy into a 4-in-1 tech combo platter.
$AIIO & $CHSN: Robo.ai ($AIIO) acquired a data compression company, and Chanson ($CHSN) is pushing AI-driven manufacturing. AI is becoming the baseline expectation, not just a novelty.
$YMAT & $MASK: $YMAT is signing MOUs for a solid-state battery facility in Texas, and $MASK is establishing a chip business unit. My take: Domestic manufacturing (chips and batteries) is politically and economically bulletproof right now. If YMAT can actually get that Texas facility funded and built, it’s a massive catalyst.
🛒 The Behemoth Doing Behemoth Things
$AMZN (Amazon): Amazon Pharmacy is expanding access to a new Ozempic® pill via same-day delivery and kiosks. My take: This is slightly terrifying but brilliant. GLP-1 drugs are the biggest pharma story of the decade. Amazon turning them into a same-day impulse buy at a kiosk? Game over for traditional pharmacies.
Final Thoughts for Monday: Keep your eyes glued to $SENS and $CRSR to see if their earnings momentum carries through the week. Be cautious with $IFRX until the offering gets absorbed, and watch $RXT to see how the market prices in that AMD relationship.
Stay disciplined, take profits when you have them, and don’t let FOMO dictate your trades!
See you in the chat,
Stock Region
LEGAL DISCLAIMER: This newsletter is a personal opinion and commentary on recent market news. It is not an offer or solicitation to buy or sell any securities. The author may hold positions in the stocks mentioned and may buy or sell them at any time without notice. We make no representations regarding the accuracy or completeness of the information provided. Investing in the stock market is speculative and carries a high degree of risk, including the possible loss of your entire investment. Please consult with a registered investment advisor before making any financial decisions.